NOVN.Q Stock Overview
NVN Liquidation, Inc., a medical dermatology company, focuses on developing and commercializing therapeutic products for skin diseases.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
NVN Liquidation, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0008 |
| 52 Week High | US$1.38 |
| 52 Week Low | US$0.000001 |
| Beta | 1.65 |
| 1 Month Change | 0% |
| 3 Month Change | 700.00% |
| 1 Year Change | -99.94% |
| 3 Year Change | -99.99% |
| 5 Year Change | -99.99% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Take Care Before Diving Into The Deep End On Novan, Inc. (NASDAQ:NOVN)
Jun 07
Novan Q2 2022 Earnings Preview
Aug 10Novan pays off $16.5M in outstanding promissory note related to EPI Health acquisition
Jul 19Novan shares under pressure after proposing capital raise
Jun 16Novan’s NVN4100 shows antimicrobial effect against bacteria in animal health
Jun 07Novan: Q2 2021's SB206 Readout Is Life Or Death For This NO-Based Biotech
Apr 28Novan regains Nasdaq compliance for minimum bid price requirement
Jan 29Novan EPS in-line, beats on revenue
Oct 30Shareholder Returns
| NOVN.Q | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0% | -2.2% | -3.7% |
| 1Y | -99.9% | 11.6% | 20.5% |
Return vs Industry: NOVN.Q underperformed the US Pharmaceuticals industry which returned 11.7% over the past year.
Return vs Market: NOVN.Q underperformed the US Market which returned 20.2% over the past year.
Price Volatility
| NOVN.Q volatility | |
|---|---|
| NOVN.Q Average Weekly Movement | 1,403.4% |
| Pharmaceuticals Industry Average Movement | 9.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: NOVN.Q's share price has been volatile over the past 3 months.
Volatility Over Time: NOVN.Q's weekly volatility has decreased from 1587% to 1403% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 90 | Scott Plesha | www.novan.com |
NVN Liquidation, Inc., a medical dermatology company, focuses on developing and commercializing therapeutic products for skin diseases. Its clinical stage dermatology drug candidates include SB204, a topical monotherapy for the treatment of acne vulgaris; SB206, a topical anti-viral gel for the treatment of viral skin infections; SB208, a topical broad-spectrum anti-fungal gel for the treatment of fungal infections of the skin and nails, including athlete’s foot and fungal nail infections; and SB414, a topical cream-based gel product candidate for the treatment of inflammatory skin diseases. The company develops SB207, an anti-viral product candidate for the treatment of external genital warts; WH602, a nitric oxide-containing intravaginal gel to treat high-risk human papilloma virus (HPV); WH504, a non-gel formulation product candidate to treat high-risk HPV; and SB019 for the treatment of SARS-CoV-2.
NVN Liquidation, Inc. Fundamentals Summary
| NOVN.Q fundamental statistics | |
|---|---|
| Market cap | US$22.41k |
| Earnings (TTM) | -US$32.05m |
| Revenue (TTM) | US$24.92m |
0.0x
P/S Ratio0.0x
P/E RatioIs NOVN.Q overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NOVN.Q income statement (TTM) | |
|---|---|
| Revenue | US$24.92m |
| Cost of Revenue | US$24.45m |
| Gross Profit | US$473.00k |
| Other Expenses | US$32.52m |
| Earnings | -US$32.05m |
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.14 |
| Gross Margin | 1.90% |
| Net Profit Margin | -128.61% |
| Debt/Equity Ratio | -1,164.1% |
How did NOVN.Q perform over the long term?
See historical performance and comparison